GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (STU:24H) » Definitions » Cyclically Adjusted Price-to-FCF

Hansa Biopharma AB (STU:24H) Cyclically Adjusted Price-to-FCF : (As of Jun. 04, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Hansa Biopharma AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Hansa Biopharma AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Hansa Biopharma AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Cyclically Adjusted Price-to-FCF Chart

Hansa Biopharma AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hansa Biopharma AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hansa Biopharma AB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Hansa Biopharma AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansa Biopharma AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

Hansa Biopharma AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Hansa Biopharma AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Hansa Biopharma AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.205/132.8245*132.8245
=-0.205

Current CPI (Mar. 2025) = 132.8245.

Hansa Biopharma AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.059 99.995 -0.078
201509 -0.054 100.228 -0.072
201512 -0.056 100.276 -0.074
201603 -0.058 100.751 -0.076
201606 -0.073 101.019 -0.096
201609 -0.090 101.138 -0.118
201612 -0.082 102.022 -0.107
201703 -0.131 102.022 -0.171
201706 -0.114 102.752 -0.147
201709 -0.116 103.279 -0.149
201712 -0.082 103.793 -0.105
201803 -0.115 103.962 -0.147
201806 -0.129 104.875 -0.163
201809 -0.136 105.679 -0.171
201812 -0.145 105.912 -0.182
201903 -0.242 105.886 -0.304
201906 -0.185 106.742 -0.230
201909 -0.190 107.214 -0.235
201912 -0.182 107.766 -0.224
202003 -0.279 106.563 -0.348
202006 -0.185 107.498 -0.229
202009 0.010 107.635 0.012
202012 -0.213 108.296 -0.261
202103 -0.269 108.360 -0.330
202106 -0.254 108.928 -0.310
202109 -0.291 110.338 -0.350
202112 -0.255 112.486 -0.301
202203 -0.279 114.825 -0.323
202206 -0.287 118.384 -0.322
202209 -0.267 122.296 -0.290
202212 -0.217 126.365 -0.228
202303 -0.353 127.042 -0.369
202306 -0.299 129.407 -0.307
202309 -0.310 130.224 -0.316
202312 -0.293 131.912 -0.295
202403 -0.318 132.205 -0.319
202406 -0.266 132.716 -0.266
202409 -0.193 132.304 -0.194
202412 -0.265 132.987 -0.265
202503 -0.205 132.825 -0.205

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Hansa Biopharma AB  (STU:24H) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Hansa Biopharma AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansa Biopharma AB Business Description

Industry
Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB Headlines

No Headlines